Journals / İbn-i Sina Tıp Dergisi / 2002 / Cilt: 7 - Sayı: 3

Multipl sklerozda beyin omirilik sıvısı ve plazma serbest aminoasit düzeyleri

Cerebrospinal fluid and plasma free amino acid levels in multilple sclerosis

Pages
143–149
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

MS patients had significantly higher CSF Thr, Gln, Tyr and Phe and plasma Thr, Ser, Gln, and Gly levels, and plasma/CSF a.a. ratio when compared to healthy controls.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Some peptides and excitatory amino acids are claimed to be involved in the pathophysiology of multiple sclerosis (MS).
📊
Key Findings & Data:Ten MS patients and 10 healthy subjects were included in this study.
💡
Conclusion & Impact:MS patients had significantly higher CSF Thr, Gln, Tyr and Phe and plasma Thr, Ser, Gln, and Gly levels, and plasma/CSF a.a. ratio when compared to healthy controls.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Beyin omurilik sıvısı · Multipl skleroz · Amino asitler

Abstract

Some peptides and excitatory amino acids are claimed to be involved in the pathophysiology of multiple sclerosis (MS). Thus, we aimed to investigate cerebrospinal fluid (CSF) and plasma amino acid (a.a.) levels in MS patients and healthy subjects and to compare the two groups of subjects in terms of a.a content of CSF and plasma. Ten MS patients and 10 healthy subjects were included in this study. Plasma and CSF a.a. levels were determined by HPLC method with Pickering post-column derivatization. For CSF, while there was no significant difference between MS and control groups in terms of total, essential, glucoketogenic, standard and derivated a.a. contents, nonessential (p<0.05) and glucogenic (p<0.05) a.a. contents were found higher in the patients. For plasma, while no significant difference was present with respect to essential, glucoketogenic and derivated a.a. contents, total (p<0.001), nonessential (p<0.001), glucogenic (p<0.001) and standard (p<0.001) a.a. contentswere found increased in MS patients. Plasma/CSF a.a. ratios were 1.51 and 1.99 in the control and MS groups, respectively. MS patients had significantly higher CSF Thr, Gln, Tyr and Phe and plasma Thr, Ser, Gln, and Gly levels, and plasma/CSF a.a. ratio when compared to healthy controls.

Özet

Multipl sklerozun (MS) patofizyolojisiyle bazı peptidler ve aminoasitlerin ilişkili olduğu öne sürülmüştür. Dolayısıyla, beyin omurilik sıvısı (BOS) ve plazma amino asit (a.a) düzeylerini MS hastalarında ve sağlıklı bireylerde incelemeyi ve iki grubu karşılaştırmayı amaçladık. 10 MS hastası ile 10 sağlıklı birey çalışmaya alındı. Plazma ve BOS a.a düzeyleri Pickering post kolon derivatizasyon HPLC yöntemiyle tayin edildi. BOS için, total, esansiyel, glukoketojenik, standart ve türev a.a miktarları MS ve kontrol grupları arasında anlamlı farklılık göstermezken, nonesansiyel (p<0.05) ve glukojenik (p<0.05) a.a miktarları hastalarda daha yüksek bulundu. Plazma için, esansiyel, glukoketojenik ve türev a.a miktarları anlamlı farklılık göstermezken; total (p<0.001), nonesansiyel (p<0.001), glukojenik (p<0.001) ve standart (p<0.001) a.a miktarları MS li hastalarda yüksek bulundu. Plazma/BOS a.a oranları kontrol grubunda 1.51 ve MS grubunda 1.99 idi. MS hastaları sağlıklı kontrollerle karşılaştırıldığında daha yüksek BOS Thr, Gln, Tyr, Phe ve plazma Thr, Sev, Gln, Gly düzeyleri ile plazma/BOS a.a oranına sahipti.

🔖

Cite This Article

KELEŞ, M. S., TAYSİ, S., BAKAN, E. (2002). Multipl sklerozda beyin omirilik sıvısı ve plazma serbest aminoasit düzeyleri. İbn-i Sina Tıp Dergisi, Cilt: 7 - Sayı: 3, 143–149. https://ajindex.com/articles/284748

References (15)

  1. Raine CS, Traugott U Immunopathology of the lesion in multiple sclerosis and chronic relapsing experimental allergic encephalomyelitis. Immunoregulatory processes in experimental allergic encephalomyelitis and multiple sclerosis. In: Vandenpark AA, Paus Jem, eds. Elsevier, Amsterdam: pp: 151-212, 1984
  2. Waksman BH (1985) Mechanisms in multiple sclerosis. Nature (Lond.) 318: 104- 105
  3. Piek J., Boldt-Götth A., Wieczorek D. and Bock W.J Cerebrospinal fluid free amino acids in patients with spinal space- occupying lesions. A preliminary report 1: Acta Neurochir (Wien) 78 (1-2): 43- 455, 1985
  4. Heiblim DL, Evans HE., Glass L and Agbayani MM Child Neurology: Amino acid concentrations in cerebrospinal fluid. Arch Neurol 35: 765-68, 1978
  5. Klivenyi P., Kekesi K., Juhasz G and Vecsei L Amino acid concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 95: 96-98, 1997
  6. Spink DC, Swann JW., Snead OC, Waniewski RA and Martin DL1 Analysis of aspartate and glutamate in human cerebrospinal fluid by high-performance liquid chromatography with automated precolumn derivatization. Anal Biochem 158: 79-86, 1986
  7. Weitz R-, Merlob P., Amir J and Reisner SH A possible role for aspartic acid in neonatal seizures. Arch Neurol 38(4): 258-59, 1981
  8. Pickering Laboratories, Inc User's Manual Amino Acids. 1951 Colony Street, Suite S Mountain View, CA 94043 USA. 1998
  9. Baig S., Halawa I and Qureshi GA High- performance liquid chromatography as a tool in the definition of abnormalities in monoamine and tryptophan metabolities in cerebrospinal fluid from patients with neurological disorders. Biomed Chromatogr5: 108-112, 1991
  10. Poser CM., Paty DW., Scheinberg L, et al. New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann Neurol 13: 227-231, 1983
  11. Link H and Tibbling G Principle of albumin and lgG in neurological disorders
  12. Relation of the concentration of the proteins in serum and the CSF. Scand J Clin Lab Invest 37: 391-395, 1977. >
  13. Pickering Laboratories, Inc Product Catolog No 2 HPLC Post-column Derivatization Instruments, Columns, Methods, Chemicals, Reagents 1951 Colony Street, Suite S Mountain View, CA 94043 USA. Pp; 55. 1997
  14. Merrill JE Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immundeficiency syndrome. J Immunother 12: 167-70, 1992
  15. Vecsei L., Csala B., Widerlov E., Ekman R and Palffy G Lumbar cerebrospin